Clinical Trials
22 trialsNCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06424717 2024-09-27
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
Phase 2 Withdrawn
NCT05574504 2024-08-01
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
Phase 2 Withdrawn
NCT05894447 2024-04-12
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT06018116 2024-02-15
CANUCK-01
CHU de Quebec-Universite Laval
Phase 2 Withdrawn
NCT02232646 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Sumitomo Pharma America, Inc.
Phase 2 Withdrawn
NCT06050954 2023-11-09
CARMA
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT05107427 2023-04-18
AVENU
4D pharma plc
Phase 2 Withdrawn
NCT05496192 2023-04-14
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT05234606 2022-04-12
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Phase 1/2 Withdrawn
NCT04179110 2022-02-22
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Yale University
Phase 2 Withdrawn
NCT03517995 2020-05-28
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT04006691 2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT03238664 2018-01-02
Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors
University of Southern California
Phase NA Withdrawn
NCT01071928 2015-08-19
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT00696007 2012-02-17
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
Lahey Clinic
Phase 2 Withdrawn
NCT00172367 2008-09-26
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Withdrawn